TABLE 2.

Demographic data for all patients

Characteristic	Linezolid- treated patients (n = 2,046)		Comparator-treated patientsa (n = 2,001)
	No.	%	No.	%
Sex
Male	1,212	59.2	1,152	57.6
Female	834	40.8	849	42.4
Age (yr)b
<18	10	0.5	8	0.4
18 to 44	816	39.9	814	40.7
45 to 64	631	30.8	602	30.1
≥65	589	28.8	577	28.8
Race
White	1,453	71.0	1,421	71.0
Black	207	10.1	223	11.1
Asian or Pacific Islander	125	6.1	136	6.8
Otherc	261	12.8	221	11.0
Presenting infection
Pneumonia	908	44.4	874	43.7
Skin or soft tissue	1,070	52.3	1,064	53.2
Other	68	3.3	63	3.1
Geographic regiond
North America	933	45.6	926	46.3
Latin America	343	16.8	321	16.0
Europe	652	31.9	635	31.7
Asia and Pacific	118	5.8	119	5.9

^aFor all comparator-treated patients, the treatments consisted of ceftriaxone and cefpodoxime (n = 366), cefpodoxime (n = 266), vancomycin (n = 413), clarithromycin (n = 537), and oxacillin and dicloxacillin (n = 419).

^bThe mean ± SD ages for the linezolid and comparator-treated patients were 51.0 ± 19.2 and 50.8 ± 19.5 years, respectively.

^cIncludes “not allowed to ask,” “mixed,” and “missing” responses.

^dNorth America, United States and Canada; Latin America, Mexico and South America; Europe, Europe, Israel, South Africa, and Australia.